Oxford BioMedica

Oxford BioMedica is a biopharmaceutical company based in the United Kingdom, specializing in gene and cell therapy, with a strong emphasis on lentiviral vector technology. The company develops and manufactures innovative therapies that deliver therapeutic DNA into patients' cells, addressing diseases that are currently underserved or lack effective treatments, including ocular and central nervous system disorders. Oxford BioMedica has a diverse pipeline featuring seven gene and cell therapy candidates aimed at transforming treatment options in these areas. Additionally, the company operates a revenue-generating platform that focuses on bioprocessing and development services for third parties, which is its primary source of revenue. The organization aims to advance its product candidates to critical value inflection points while enhancing its manufacturing and development services.